Lineage Cell Therapeutics, INC 8-K filings

Lineage Cell Therapeutics reports annual meeting voting results and the withdrawal of a CIRM grant application for OPC1.

Lineage Cell Therapeutics reported Q1 2026 financial results, highlighting positive Phase 1/2a data for OpRegen, the launch of a new corneal cell therapy program (COR1), and advancements in manufacturing technology.

Lineage Cell Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting significant clinical and manufacturing advancements alongside increased net losses driven by non-cash expenses.

Lineage Cell Therapeutics, Inc. withdrew its CIRM grant application for OPC1 spinal cord injury treatment but plans to resubmit in January 2026 without impacting current development.

Lineage Cell Therapeutics, Inc. announced the achievement of a key development milestone for its OpRegen program, triggering a $5 million payment from Genentech and Roche.

Lineage Cell Therapeutics, Inc. announced the sale of 12 million common shares to Janus Henderson Investors for $21 million in gross proceeds.

Lineage Cell Therapeutics announced its third quarter 2025 financial results, highlighting progress in its cell therapy programs and a significant increase in net loss primarily due to warrant liability remeasurement.

Lineage Cell Therapeutics announced a multi-year research collaboration with William Demant Invest to advance its ReSonance program for hearing loss, with WDI funding up to $12 million.

Lineage Cell Therapeutics announced its second quarter 2025 financial results, highlighting positive 36-month clinical data for its OpRegen cell therapy and a milestone in its OPC1 spinal cord injury program.

Lineage Cell Therapeutics, Inc. shareholders approved the election of seven directors, ratified the appointment of Baker Tilly US, LLP as independent auditor, approved executive compensation on an advisory basis, and significantly increased the shares available under the 2021 Equity Incentive Plan by 19.5 million at their annual meeting on June 26, 2025.

Lineage Cell Therapeutics announced positive 36-month visual acuity and retinal structural improvement results from its Phase 1/2a clinical study of OpRegen (RG6501) for geographic atrophy secondary to age-related macular degeneration.

Lineage Cell Therapeutics, Inc. announced the appointment of Baker Tilly US, LLP as its new independent registered public accounting firm for the fiscal year ending December 31, 2025, following the merger of its previous auditor, Moss Adams LLP, with Baker Tilly.

Lineage Cell Therapeutics announced its Q1 2025 financial results, highlighting progress in its OpRegen and OPC1 programs and a cash runway into Q1 2027.

Lineage Cell Therapeutics successfully completes a production run for two product candidates using a customized cGMP cell banking system, demonstrating potential for scalable manufacturing.

Lineage Cell Therapeutics announces positive clinical data for OpRegen, a services agreement with Genentech, and financial results for 2024, with cash runway extended into Q1 2027.

Lineage Cell Therapeutics finalized the second tranche of its registered direct offering, securing $6 million and anticipating up to $36 million more from warrant exercises linked to a clinical milestone.

Lineage Cell Therapeutics has announced a registered direct offering to raise up to $66 million, including $30 million upfront and a potential additional $36 million upon full exercise of clinical milestone-linked warrants.

Lineage Cell Therapeutics announced its third quarter 2024 financial results, highlighted by increased revenue and progress in its clinical programs, including RMAT designation for OpRegen.

Lineage Cell Therapeutics announced its second quarter 2024 financial results, highlighting clinical progress with OpRegen and preparations for the OPC1 clinical study.

Lineage Cell Therapeutics has dismissed WithumSmith+Brown, PC and appointed Moss Adams LLP as its new independent registered public accounting firm, effective June 11, 2024.

Lineage Cell Therapeutics amended its bylaws and held its annual shareholder meeting, electing directors and ratifying the appointment of its accounting firm.

Lineage Cell Therapeutics has filed a prospectus supplement for an at-the-market offering of common shares, aiming to raise up to $39.9 million.

Lineage Cell Therapeutics reported its first quarter 2024 financial results, highlighted by a new services agreement with Genentech and progress in its clinical programs.

Lineage Cell Therapeutics has entered into a sales agreement with B. Riley Securities for potential at-the-market share offerings and received an update from the FDA regarding its OPC1 clinical study.

Lineage Cell Therapeutics announced its fourth quarter and full year 2023 financial results, highlighting progress in its clinical programs and a strengthened balance sheet.

Lineage Cell Therapeutics has announced the date for its 2024 annual shareholder meeting and established deadlines for shareholder proposals and director nominations.

Lineage Cell Therapeutics has entered into a definitive agreement for a $14 million registered direct offering of common shares.